Literature DB >> 33048801

[Simultaneous diagnosis and favorable evolution of infection with Pneumocystis jirovecii, SARS-CoV-2 and advanced HIV].

Francisco J Larzábal1, Andrés Vilela2, Silvia Brusca2, Irene Saluzzi2, Gisela E Ghergo2, María Antonela Angiono3.   

Abstract

SARS-CoV-2 causes the disease named COVID-19, which emerged in Wuhan, China, in December 2019 and developed into the current pandemic. The manifestations of SARS-CoV-2 infection are highly variable. The worst outcomes are usually associated with advanced age and known risk factors. Among these, it would be reasonable to consider conditions compromising the immune system, particularly the immunodeficiency associated to HIV. To date, however, there is no evidence of HIV infection worsening the evolution and prognosis of COVID-19. Pneumocystis jirovecii (previously-P. carinii) pneumonia, is a fungal disease that most commonly affects immunocompromised persons and can be life-threatening. Typically, patients at risk are those with any underlying condition altering host immunity. We present the case of a middle-aged woman with Raynaud's syndrome who was admitted with pneumonia. During hospitalization she was simultaneously diagnosed with infection by HIV, COVID-19 and P. jirovecci. The patient evolved favorably upon empirical treatment without requiring invasive maneuvers or ventilatory support. Outpatient follow-up after hospital discharge was uneventful.

Entities:  

Keywords:  COVID-19; HIV; Pneumocysti jiroveccii

Mesh:

Year:  2020        PMID: 33048801

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  5 in total

Review 1.  HIV and COVID-19 in Latin America and the Caribbean.

Authors:  Patricia J Garcia; Diego M Cabrera; Paloma M Cárcamo; Monica M Diaz
Journal:  Curr HIV/AIDS Rep       Date:  2022-01-29       Impact factor: 5.495

2.  Successful treatment of a kidney transplant patient with COVID-19 and late-onset Pneumocystis jirovecii pneumonia.

Authors:  Jing Peng; Ming Ni; Dunfeng Du; Yanjun Lu; Juan Song; Weiyong Liu; Na Shen; Xiong Wang; Yaowu Zhu; Bruce A Vallance; Ziyong Sun; Hong Bing Yu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-12-15       Impact factor: 3.944

Review 3.  Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals.

Authors:  Francesca Gioia; Hanan Albasata; Seyed M Hosseini-Moghaddam
Journal:  J Fungi (Basel)       Date:  2022-05-30

Review 4.  The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review.

Authors:  Nahid Akhtar; Atif Khurshid Wani; Surya Kant Tripathi; Ajit Prakash; M Amin-Ul Mannan
Journal:  Curr Res Biotechnol       Date:  2022-08-03

Review 5.  Epidemiology of Systemic Mycoses in the COVID-19 Pandemic.

Authors:  María Guadalupe Frías-De-León; Rodolfo Pinto-Almazán; Rigoberto Hernández-Castro; Eduardo García-Salazar; Patricia Meza-Meneses; Carmen Rodríguez-Cerdeira; Roberto Arenas; Esther Conde-Cuevas; Gustavo Acosta-Altamirano; Erick Martínez-Herrera
Journal:  J Fungi (Basel)       Date:  2021-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.